Page 66 - SDIR5 Abstract book 21 12 2021.

POSTER PRESENTATIONS

P26

Anti-obesity drug Orlistat (Xenical®) induces antiangiogenic potential in breast cancer cell
lines

Jovana V. Jovankić , Danijela D. Nikodijević , Milena G. Milutinović , Aleksandra G. Nikezić , Nevena S.
1
1*
1
1
1
1
Planojević , Stefan Z. Blagojević , Danijela M. Cvetković 2
1 University of Kragujevac, Faculty of Science, Department of Biology and Ecology, Radoja Domanovića 12, 34000
Kragujevac, Serbia
2 University of Kragujevac, Institute for Information Technologies Kragujevac, Department of Natural Sciences,
Jovana Cvijića bb, 34000 Kragujevac, Serbia

Background: Obesity is one of the risk factors for development of breast cancer among women. Human
breast cancer is a heterogeneous group of invasive tumors with a specific response to therapy, so treating
and preventing this disease is difficult. The modern lifestyle imposes daily unhealthy habits which may
contribute to the development of obesity-associated breast cancer. A great effort has been made to
investigate non-standard drugs to improve treatment protocols. Orlistat as US Food and Drug
Administration-approved drug for bodyweight loss has been demonstrated to exhibit antitumor properties
towards breast cancer cells by its ability to induce cytotoxic, proapoptotic, antiangiogenic, and
antimetastatic effects. Material and Methods: The immunocytochemistry staining method was used to
evaluate the protein expression of CXCR-4, VEGF165b, MMP-9 as angiogenic markers in triple-negative
breast cancer cell lines (MDA-MB-231 and MDA-MB-468) under the influence of Orlistat in two doses (1
and 25 µg/ml). Results: Angiogenic factors are highly expressed in obesity-linked breast cancer, maintaining
tumor progression and angiogenesis, so their suppression may result in a positive outcome in patients'
therapy. Our results indicate that treatment whit Orlistat induces a significant dose-dependent suppression
of monitored parameters in breast cancer cell lines concerning control values. The MDA-MB-468 cells were
more sensitive to the applied drug, which is linked to poor aggressiveness, compared whit highly aggressive
MDA-MB-231 cells originated from same organ. Conclusion: Based on our results Orlistat can be considered
as a novel inhibitor of CXCR-4, VEGF165b, and MMP-9 which are strongly linked to cancer progression,
angiogenesis, and metastasis.
Keywords: angiogenesis, breast cancer, CXCR-4, MMP-9, orlistat, VEGF165b

53